Kono M, Komatsuda H, Yamaki H, Kumai T, Hayashi R, Wakisaka R, et al. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. Oncoimmunology. 2022;11:2021619 pubmed publisher

Forlani G, Tosi G, Turrini F, Poli G, Vicenzi E, Accolla R. Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1. Front Immunol. 2017;8:564 pubmed publisher

Forlani G, Turrini F, Ghezzi S, Tedeschi A, Poli G, Accolla R, et al. The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells. J Transl Med. 2016;14:94 pubmed publisher

Martins I, Deshayes F, Baton F, Forget A, Ciechomska I, Sylla K, et al. Pathologic expression of MHC class II is driven by mitogen-activated protein kinases. Eur J Immunol. 2007;37:788-97 pubmed

Kohoutek J, Blazek D, Peterlin B. Hexim1 sequesters positive transcription elongation factor b from the class II transactivator on MHC class II promoters. Proc Natl Acad Sci U S A. 2006;103:17349-54 pubmed